Taken together these results strongly support that the expression of the FUS-DDIT3 oncogene is able to block the adipocyte differentiation program of target mesenchymal progenitor cells interacting with the PPARγ and C/EBPα pathways (Figure 7) and contributing to generate a transformed phenotype, similarly to other fusion oncogenes associated to hematopoietic malignances, such as BCR-ABLp190[41] and PML-RARα [42]. Here, DDIT3 is linked to cancer.